New drug shows promise against Hard-to-Treat cancers
NCT ID NCT04225117
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an experimental drug called enfortumab vedotin in 329 adults with advanced solid tumors that have spread. The main goal is to see if the drug shrinks tumors. Researchers also check how long the effect lasts and monitor side effects. Some participants also receive another drug, pembrolizumab.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HR+/HER2- BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Arizona Oncology
Tucson, Arizona, 85711, United States
-
Cleveland Clinic
Cleveland, Ohio, 44195, United States
-
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada, 89169, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Florida Cancer Specialists
Fort Myers, Florida, 33901, United States
-
Florida Cancer Specialists
Tallahassee, Florida, 32308, United States
-
Florida Cancer Specialists
West Palm Beach, Florida, 33401, United States
-
Gettysburg Cancer Center
Gettysburg, Pennsylvania, 17375, United States
-
Henry Ford Hospital
Detroit, Michigan, 48202, United States
-
Indiana University Cancer Center
Indianapolis, Indiana, 46202, United States
-
Mary Crowley Research Center
Dallas, Texas, 75230, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10022, United States
-
Nebraska Methodist Hospital
Omaha, Nebraska, 68114, United States
-
New York University Langone Health
New York, New York, 10016, United States
-
Northside Hospital
Atlanta, Georgia, 30342, United States
-
Northwestern University Medical Center
Chicago, Illinois, 60611, United States
-
Ohio State University
Columbus, Ohio, 43210, United States
-
Piedmont Hospital
Atlanta, Georgia, 30318, United States
-
Rutgers Cancer Institute
New Brunswick, New Jersey, 08901, United States
-
Sarah Cannon Research Institute
Nashville, Tennessee, 37203, United States
-
Seattle Cancer Care Alliance
Seattle, Washington, 98109, United States
-
Site CA15003
Ottawa, Ontario, K1H 8L6, Canada
-
Site JP81001
Kashiwa, Chiba, Japan
-
Site JP81002
Koto, Tokyo, Japan
-
Site JP81003
Chūō, Tokyo, Japan
-
Site JP81004
Nagoya, Aichi-ken, Japan
-
Site JP81005
Chuo-ku, Osaka, Japan
-
Site JP81006
Nakatogari, Shizuoka, Japan
-
Site JP81007
Ōsaka-sayama, Osaka, Japan
-
Site JP81010
Okayama, Japan
-
Site JP81011
Kitaadachi-Gun, Saitama, Japan
-
University of California - San Francisco
San Francisco, California, 94158, United States
-
University of Chicago
Chicago, Illinois, 60637, United States
-
University of Colorado
Aurora, Colorado, 80045, United States
-
University of Kansas
Fairway, Kansas, 66205, United States
-
University of Michigan
Ann Arbor, Michigan, 48109, United States
-
University of Minnesota Cancer Center
Minneapolis, Minnesota, 55455, United States
-
University of Texas
Houston, Texas, 77030, United States
-
Wisconsin Carbone Cancer Center
Madison, Wisconsin, 53792, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Chemo-Free hope: new pill combo targets Hard-to-Treat breast cancer
- Could two years of hormone therapy be enough for some breast cancers?
- Could a targeted drug re-sensitize resistant breast cancer?
- AI reads MRI scans to predict who will benefit from chemo
- Three-Drug cocktail aims to shrink breast tumors before surgery
- Radioactive 'Smart Bombs' target Hard-to-Treat cancers